Distinct Serum Immune Profiles Define the Spectrum of Acute and Chronic Pancreatitis From the Multicenter Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) Study.
Alcohol
Immunity
Pancreatitis
Serum
Smoking
Journal
Gastroenterology
ISSN: 1528-0012
Titre abrégé: Gastroenterology
Pays: United States
ID NLM: 0374630
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
14
11
2022
revised:
21
03
2023
accepted:
30
03
2023
pmc-release:
01
07
2024
medline:
26
6
2023
pubmed:
16
4
2023
entrez:
15
4
2023
Statut:
ppublish
Résumé
Pancreatitis is a disease continuum, starting with acute pancreatitis (AP) and progressing in some cases to recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP). Currently, there are no approved therapies or early diagnostic or prognostic biomarkers for pancreatitis. The current study examined whether patient serum immune profiling could identify noninvasive biomarkers and provide mechanistic insight into the disease continuum of pancreatitis. Using Olink immunoassay, we assessed the protein levels of 92 immune markers in serum samples from participants enrolled in the Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) study of the Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) consortium. Samples (N = 231) were obtained from individuals without pancreatic disease (n = 56) and from those with chronic abdominal pain (CAP) (n = 24), AP (n = 38), RAP (n = 56), and CP (n = 57). A total of 33 immune markers differentiated the combined pancreatitis groups from controls. Immune markers related to interleukin (IL) 17 signaling distinguished CP from AP and RAP. Similarly, the serum level of IL17A and C-C motif chemokine ligand 20 differentiated CP from CAP, suggesting the involvement of T helper 17 cells in CP pathogenesis. The receiver operator characteristic curve with 2 immune markers (IL17A and sulfotransferase 1A1) could differentiate CP from CAP (optimistic area under the curve = 0.78). The macrophage classical activation pathway elevated along the continuum of pancreatitis, suggesting an accumulation of proinflammatory signals over disease progression. Several immune markers were associated with smoking, alcohol, and diabetes status. Immune profiling of serum samples from a large pancreatitis cohort led to identifying distinct immune markers that could serve as potential biomarkers to differentiate the varying pancreatitis disease states. In addition, the finding of IL17 signaling in CP could provide insight into the immune mechanisms underlying disease progression.
Sections du résumé
BACKGROUND & AIMS
OBJECTIVE
Pancreatitis is a disease continuum, starting with acute pancreatitis (AP) and progressing in some cases to recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP). Currently, there are no approved therapies or early diagnostic or prognostic biomarkers for pancreatitis. The current study examined whether patient serum immune profiling could identify noninvasive biomarkers and provide mechanistic insight into the disease continuum of pancreatitis.
METHODS
METHODS
Using Olink immunoassay, we assessed the protein levels of 92 immune markers in serum samples from participants enrolled in the Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED) study of the Chronic Pancreatitis, Diabetes, and Pancreatic Cancer (CPDPC) consortium. Samples (N = 231) were obtained from individuals without pancreatic disease (n = 56) and from those with chronic abdominal pain (CAP) (n = 24), AP (n = 38), RAP (n = 56), and CP (n = 57).
RESULTS
RESULTS
A total of 33 immune markers differentiated the combined pancreatitis groups from controls. Immune markers related to interleukin (IL) 17 signaling distinguished CP from AP and RAP. Similarly, the serum level of IL17A and C-C motif chemokine ligand 20 differentiated CP from CAP, suggesting the involvement of T helper 17 cells in CP pathogenesis. The receiver operator characteristic curve with 2 immune markers (IL17A and sulfotransferase 1A1) could differentiate CP from CAP (optimistic area under the curve = 0.78). The macrophage classical activation pathway elevated along the continuum of pancreatitis, suggesting an accumulation of proinflammatory signals over disease progression. Several immune markers were associated with smoking, alcohol, and diabetes status.
CONCLUSIONS
CONCLUSIONS
Immune profiling of serum samples from a large pancreatitis cohort led to identifying distinct immune markers that could serve as potential biomarkers to differentiate the varying pancreatitis disease states. In addition, the finding of IL17 signaling in CP could provide insight into the immune mechanisms underlying disease progression.
Identifiants
pubmed: 37061168
pii: S0016-5085(23)00594-2
doi: 10.1053/j.gastro.2023.03.236
pmc: PMC10330331
mid: NIHMS1893093
pii:
doi:
Substances chimiques
Biomarkers
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
173-186Subventions
Organisme : NIDDK NIH HHS
ID : U01 DK108288
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK108323
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK108332
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK108326
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK126300
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK108320
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK126365
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK108328
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK108300
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK108306
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK108314
Pays : United States
Organisme : NIDDK NIH HHS
ID : U01 DK108327
Pays : United States
Investigateurs
Liang Li
(L)
Dhiraj Yadav
(D)
Darwin L Conwell
(DL)
Phil A Hart
(PA)
Santhi Swaroop Vege
(SS)
Evan L Fogel
(EL)
Jose Serrano
(J)
Dana Andersen
(D)
Melena D Bellin
(MD)
Mark Topazian
(M)
Stephen K Van Den Eeden
(SK)
Stephen J Pandol
(SJ)
Chris Forsmark
(C)
William E Fisher
(WE)
Walter G Park
(WG)
Informations de copyright
Copyright © 2023 AGA Institute. All rights reserved.
Références
Clin Chim Acta. 2018 Jan;476:44-48
pubmed: 29132901
Dig Dis Sci. 2017 Jul;62(7):1683-1691
pubmed: 28281168
Gastroenterology. 2012 Dec;143(6):1670-80
pubmed: 23022954
Best Pract Res Clin Gastroenterol. 2010 Jun;24(3):349-58
pubmed: 20510834
Am J Gastroenterol. 2017 Sep;112(9):1457-1465
pubmed: 28741615
J Exp Med. 2007 Nov 26;204(12):2803-12
pubmed: 18025126
Gut. 2019 Oct;68(10):1827-1837
pubmed: 30705050
Clin Gastroenterol Hepatol. 2016 May;14(5):738-46
pubmed: 26772149
BMC Bioinformatics. 2008 Feb 25;9:114
pubmed: 18298808
World J Gastroenterol. 2006 Oct 21;12(39):6249-51
pubmed: 17072944
Gastroenterology. 2010 Mar;138(3):1178-88
pubmed: 19931255
PLoS One. 2014 Apr 22;9(4):e95192
pubmed: 24755770
J Pediatr. 2021 Nov;238:33-41.e4
pubmed: 34273357
J Stat Softw. 2010;33(1):1-22
pubmed: 20808728
Gut. 2022 Sep;71(9):1831-1842
pubmed: 34702715
Nat Commun. 2015 May 18;6:7158
pubmed: 25981357
Curr Opin Gastroenterol. 2021 Sep 1;37(5):526-531
pubmed: 34074860
Immunity. 2019 Feb 19;50(2):446-461.e9
pubmed: 30709742
Front Neurol. 2022 Jun 06;13:889647
pubmed: 35734478
Arch Intern Med. 2009 Jun 8;169(11):1035-45
pubmed: 19506173
Pancreas. 2018 Nov/Dec;47(10):1213-1221
pubmed: 30325860
J Biol Chem. 2011 Apr 15;286(15):13327-35
pubmed: 21343291
Gastroenterology. 2013 Jun;144(6):1252-61
pubmed: 23622135
Atherosclerosis. 2008 Aug;199(2):440-4
pubmed: 18054361
Cytokine. 2018 Mar;103:90-98
pubmed: 28982582
J Invest Dermatol. 2009 Sep;129(9):2175-83
pubmed: 19295614
J Clin Endocrinol Metab. 2013 Aug;98(8):3482-90
pubmed: 23760626
Pancreas. 2011 Nov;40(8):1195-200
pubmed: 21926938
Curr Opin Gastroenterol. 2015 Sep;31(5):395-9
pubmed: 26107390
ScientificWorldJournal. 2007 Mar 30;7:431-48
pubmed: 17450307
Surg Gynecol Obstet. 1988 Oct;167(4):282-6
pubmed: 3047892
Gastroenterology. 2012 Nov;143(5):1179-1187.e3
pubmed: 22885331
Sci Rep. 2021 Jan 14;11(1):1367
pubmed: 33446814
Invest Ophthalmol Vis Sci. 2013 Jun 12;54(6):4081-91
pubmed: 23702781
Gastroenterology. 2016 Dec;151(6):1206-1217
pubmed: 27769811
Gastroenterology. 2021 Dec;161(6):2014-2029.e14
pubmed: 34450180
Theranostics. 2018 Aug 10;8(16):4552-4562
pubmed: 30214638
J Immunol. 2018 Mar 15;200(6):2104-2114
pubmed: 29440506
Cytokine. 2004 Feb 21;25(4):187-91
pubmed: 15164724
Pancreatology. 2005;5(2-3):177-82
pubmed: 15849488
Pancreas. 2018 Nov/Dec;47(10):1229-1238
pubmed: 30325862
Clin Gastroenterol Hepatol. 2011 Mar;9(3):266-73; quiz e27
pubmed: 21029787
Lancet Gastroenterol Hepatol. 2016 Sep;1(1):45-55
pubmed: 28404111
Gastroenterology. 2015 Nov;149(6):1490-1500.e1
pubmed: 26299411
Pancreatology. 2020 Jan;20(1):51-59
pubmed: 31791885
Proteomics. 2022 Jul;22(13-14):e2100170
pubmed: 35598103